1Sugimoto T, Gotoh T , Yagyu S, Kuroda H, Iehara T, Hosoi H, et al. (2013) A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines. Cancer Lett., 331: 115–121.

2Tsokos M, Webber BL, Parham DM, Wesley RA, Miser JS , et al. (1992) Rhabdomyosarcoma. A new classification scheme related to prognosis. Arch. Pathol. Lab. Med., 116: 847–855.

3Hosoi H, Sugimoto T, Hayashi Y, Inaba J, Horii Y, Morioka H, et al. (1992) Differential expression of myogenic regulatory genes, MyoD1 and myogenin, in human rhabdomyosarcoma sublines. Int. J. Cancer 50: 977–983.

4Sugimoto T, Mine H, Horii Y, Takahashi K, Nagai R, et al. (2000) Neuroblastoma cell lines showing smooth muscle cell phenotypes. Diagn. Mol. Pathol 9: 221–228.

5Davis RL, Weintraub H, Lassar AB (1987) Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell, 51: 987–1000.

6Tonin PN, Scrable H, Shimada H, Cavenee WK (1991) Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res 51: 5100–5106.

7Tapscott SJ, Thayer MJ, Weintraub H (1993) Deficiency in rabdomyosarcoma of a factor required for MyoD activity and myogenesis. Science 259: 1450–1453.

8Barr FG, Galili N, Holick J, Biegel JA, Rovera G,Emanuel BS (1993) Rearrangement of the PAX3 paired box gene in the pediatric solid tumor alveolar rhabdomyosarcoma. Nat. Genet 3: 113–117.

9Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R,Lim JF, et al. (2002) PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J. Clin. Oncol., 20: 2672–2679.

10Schwab M, Alitalo K, Klempnauer KH, Varmus HE, etal. (1983) Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305: 245–248.

11Hayashi Y, Sugimoto T, Horii Y, Hosoi H, Inazawa J, Kemshead JT, et al. (1990) Characterization of an embryonal rhado-myosarcoma cell line showing amplification and over-expression of the N-myc oncogene. Int. J. Cancer 45: 705–711.

12Toffolatti L, Frascella E, Ninfo V, Gambini C, Forni M,Carli M, Rosolen A (2002) MYCN expression in human rhabdomyosarcoma cell lines and tumour samples. J. Pathol 196: 450–458.

13Dias P, Kumar P, Marsden HB, Gattamaneni HR, Heighway J, Kumar S. (1990) N-myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS. Int. J. Cancer 45: 593–596.

14Tonelli R, McIntyre A, Camerin C, Walters ZS, Leo K Di, Selfe J, et al. (2012) Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. Clin. Cancer Res., 18: 796–807.

15Mercado GE, Xia SJ, Zhang C, Ahn EH, Gustafson DM, Laé M, et al. (2008) Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chromosomes Cancer 47: 510–520.

16Williamson D, Lu YJ, Gordon T, Sciot R, Kelsey A, Fisher C, Poremba C, et al. (2005) Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J. Clin. Oncol., 23: 880–888.

17Ida K, Kobayashi S, Taki T, Hanada R, Bessho F, et al.(1995) EWS-FLI-1 and EWS-ERG chimeric mRNAs in Ewing's sarcoma and primitive neuroectodermal tumor. Int. J. Cancer, 63: 500–504.

18Moritake H, Sugimoto T, Kuroda H, Hidaka F, Takahashi Y, et al. (2003) Newly established Askin tumor cell line and overexpression of focal adhesion kinase in Ewing sarcoma family of tumors cell lines. Cancer Genet. Cytogenet 146: 102–109.

19Sugimoto T, Hosoi H, Horii Y, Ishida H, Mine H, Takahashi K, et al.et al. (1999) Malignant rhabdoid-tumor cell line showing neural and smooth-muscle-cell phenotypes. Int. J. Cancer 82: 678–686.

20Katsumi Y, Kuwahara Y, Tamura S, Kikuchi K, Otabe O, et al. (2008) Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity. Clin. Cancer Res 14: 1192–1199.

21Kuroda H, Moritake H, Sawada K, Kuwahara Y, Imoto I, Inazawa J, Sugimoto T (2005) Establishment of a cell line from a malignant rhabdoid tumor of the liver lacking the function of two tumor suppressor genes, hSNF5/INI1 and p16. Cancer Genet. Cytogenet 158:172–179.

22Hosoi H, Iehara T, Tsuchiya K, Misawa A, Miyaji M, et al. (2007) Continuous remission in an infant with chest wall malignant rhabdoid tumor after relapse. J. Pediatr. Surg 42: E9–E12.

23Misawa A, Hosoi H, Imoto I, Iehara T, Sugimoto T, Inazawa J (2004) Translocation (1; 22) (p36; q11.2) with concurrent del (22) (q11.2) resulted in the homozygous deletion of SNF5/INI1 in a newly established cell line derived from the extrarenal rhabdoid tumor. J. Hum. Genet., 49: 586–589.

24Kuwahara Y, Hosoi H, Osone S, Kita M, Iehara T, Kuroda H, Sugimoto T (2004) Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo. Clin. Cancer Res., 10: 5940–5948.

25Enzinger FM (1965) Clear-cell sarcoma of tendons and aponeuroses. An analysis of 21 cases. Cancer 18: 1163–1174.

26Moritake H, Sugimoto T, Asada Y, Yoshida M.A, Maehara Y, et al. (2002) Newly established clear cell sarcoma (malignant melanoma of soft parts) cell line expressing melanoma-associated Melan-A antigen and overexpressing C-MYC oncogene. Cancer Genet. Cytogenet 135: 48–56.

27Epstein AL, Martin AO, Kempson R (1984) Use of a newly established human cell line (SU-CCS−1) to demonstrate the relationship of clear cell sarcoma to malignant melanoma. Cancer Res 44: 1265–1274.

28Fujimoto T, Andoh T, Sudo T, Fujita I, Moritake H, Sugimoto T, et al. (2013) Boron neutron capture therapy (BNCT) selectively destroys human clear cell sarcoma in the mouse model. Appl. Radiat. Isot 73: 96–100.

29Sugimoto T, Kuroda H, Yagyu S, Gotoh T, Osone S, Tamura S, Iehara T, Hosoi H (2019) Cellular and molecular characteristics of established neuroblastoma cell lines. J Cancer Res Therap Oncol 7: 1-15.